Clinical Trial · NCT01089244

FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma

Overview

The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.

Sponsor

Unknown Organization

Contacts

Joerg C. Tonn, Prof. Dr. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01089244

Drug / Compound

FET

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • histological verification will be obtained either by microsurgery or by stereotactic biopsy
  • neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II)
  • Karnofsky Performance Score \>=70

Exclusion

  • medical history of a metastatic brain disease
  • patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.